Transaction details
Brenton Taylor, who serves as Executive Vice President of Operations & R&D at Sight Sciences, Inc. (NASDAQ: SGHT), disposed of 2,869 shares of the companys common stock on April 1, 2026, according to a Form 4 filing submitted to the Securities and Exchange Commission. The shares were sold at a weighted average price of $3.70, translating to proceeds of $10,615. Reported trade prices spanned from $3.63 to $3.85.
Post-sale ownership and rationale
Following the April 1 sale, Taylor is shown as directly holding 267,807 shares of Sight Sciences common stock. The filing states the disposition was carried out to satisfy the reporting persons tax liability associated with the vesting of restricted stock units.
Recent corporate performance
Sight Sciences also disclosed fourth-quarter 2025 financial results that outperformed analyst projections on both the earnings per share and revenue lines. Reported EPS for the quarter was -$0.08, ahead of the consensus expectation of -$0.15. Quarterly revenue totaled $20.4 million, slightly above the forecasted $20.17 million.
Legal development
In a related legal matter, Sight Sciences was awarded $34 million in a patent case against Alcon Inc. The U.S. District Court for the District of Delaware upheld a jury verdict finding that Alcon willfully infringed on three of Sight Sciences patents. The damages award comprises $5.5 million attributed to lost profits and $28.5 million in royalty damages.
Analyst response
Following these developments, William Blair reiterated an Outperform rating on Sight Sciences, citing the companys effective control of expenses. The firms stance reflects the combination of a narrower-than-expected quarterly loss, revenue marginally above estimates, and the patent damages award.
Context and limitations
The filing documents the insider sale and states it was executed to cover tax obligations tied to RSU vesting. The companys recent quarterly results and the patent award are presented in the companys disclosures and court records referenced in public filings; additional context on the longer-term financial impact of the damages award or subsequent legal developments is not provided in those statements.
Summary of facts presented: Taylor sold 2,869 shares at a weighted average of $3.70 on April 1, 2026; post-sale holdings equal 267,807 shares; sale was to cover RSU-related taxes. Sight Sciences reported Q4 2025 EPS of -$0.08 vs -$0.15 expected and revenue of $20.4M vs $20.17M expected. The company was awarded $34M against Alcon for willful infringement, comprised of $5.5M lost profits and $28.5M in royalty damages. William Blair reiterated an Outperform rating, noting expense control.